Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Diabetic Neuropathy01:22

Diabetic Neuropathy

DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...
Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
Diabetes Insipidus II: Pathophysiology01:22

Diabetes Insipidus II: Pathophysiology

Normally, water balance is maintained through three interconnected mechanisms: the hypothalamic thirst center, the synthesis and release of antidiuretic hormone (ADH, or vasopressin), and the kidneys' responsiveness to this hormone. ADH is synthesized in the hypothalamus, released from the posterior pituitary, and acts on the distal nephron, allowing water reabsorption and concentrated urine production.Diabetes Insipidus and Its TypesIn diabetes insipidus (DI), this regulatory system is...
Diabetes Insipidus I: Introduction01:29

Diabetes Insipidus I: Introduction

Definition Diabetes insipidus is a disorder marked by the production of large amounts of dilute urine because of impaired vasopressin production, release, or kidney response. The lack of effective vasopressin action limits water reabsorption in the renal collecting ducts, which leads to excessive urinary water loss and intense thirst.Clinical PresentationIndividuals with diabetes insipidus report persistent thirst and very high urine output. In severe cases, fluid intake can reach up to 20...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of Finerenone on Albuminuria in Type 1 Diabetes by Baseline HbA1c Level and Diabetes Duration: An Exploratory Analysis of the FINE-ONE Trial.

Diabetes care·2026
Same author

Shared multicellular injury programs of acute and chronic kidney disease enable mechanistic patient stratification.

medRxiv : the preprint server for health sciences·2026
Same author

Cardio-Kidney-Metabolic Therapy Use Among Adults With Type 1 Diabetes and Chronic Kidney Disease.

Diabetes, obesity & metabolism·2026
Same author

Association Between Off-Label Use of Cardio-Kidney-Metabolic Therapies and Risk of Cardiovascular Events in Type 1 Diabetes: A Real-World Evidence Study.

Diabetes, obesity & metabolism·2026
Same author

GLP-1 receptor agonists and other incretin mimetics for diabetes and chronic kidney disease-a KDIGO commentary.

Kidney international·2025
Same author

Indexing GFR Using Extracellular Volume versus Body Surface Area in a Population with Type 1 Diabetes and Diabetic Kidney Disease.

Journal of the American Society of Nephrology : JASN·2025

Related Experiment Video

Updated: May 24, 2026

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway
08:15

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway

Published on: May 10, 2024

Viper venom for diabetic nephropathy.

M Luiza Caramori

    Kidney International
    |March 16, 2012
    PubMed
    Summary

    Renin-angiotensin-aldosterone system (RAAS) inhibitors may reduce urinary albumin excretion in diabetic patients. However, their specific renoprotective benefits over other blood pressure medications remain uncertain, impacting diabetic nephropathy management.

    Area of Science:

    • Nephrology
    • Endocrinology
    • Cardiovascular Medicine

    Background:

    • Diabetic nephropathy is a primary cause of end-stage renal disease in the US.
    • Renin-angiotensin-aldosterone system (RAAS) blockers are hypothesized to offer specific kidney protection in diabetic individuals.
    • Urinary albumin excretion is a key marker for kidney damage in diabetes.

    Purpose of the Study:

    • To evaluate the impact of RAAS inhibitors on urinary albumin excretion in diabetic patients.
    • To determine if RAAS inhibitors provide superior renoprotection compared to other antihypertensive drugs.

    Main Methods:

    • Systematic review and meta-analysis of randomized clinical trials.
    • Assessment of urinary albumin excretion levels as the primary outcome.

    Related Experiment Videos

    Last Updated: May 24, 2026

    Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway
    08:15

    Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway

    Published on: May 10, 2024

  • Comparison of RAAS inhibitors against placebo or other antihypertensive agents.

    • Main Results:

    • RAAS inhibitors demonstrated a reduction in urinary albumin excretion in diabetic patients.
    • The comparative renoprotective advantage of RAAS inhibitors over other antihypertensives was not definitively established.
    • Heterogeneity in study designs and patient populations may influence findings.

    Conclusions:

    • While RAAS inhibitors show promise in reducing albuminuria in diabetes, their unique renoprotective role requires further investigation.
    • Clinical guidelines should consider the current evidence regarding RAAS inhibitors for diabetic nephropathy.
    • Future research should focus on head-to-head trials to clarify the comparative efficacy of different antihypertensive classes.